MedTrace Logo

Vitamin D Supplementation and Neurocognition

NCT03019120 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-02-26

No results posted yet for this study

Summary

This study will evaluate the effect of vitamin D supplementation on the neurocognitive function of older people with lower than normal levels of vitamin D at baseline

Conditions

  • Vitamin D Deficiency
  • Neurocognitive Dysfunction

Interventions

DRUG

Vitamin D

1. Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery. 2. Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months. 3. Levels of serum calcium will be repeated monthly (end of month 1, 2, 3). 4. Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up. 5. At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery.

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Elad Rubin, M.A · Rambam Health Care Campus

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-15
Primary Completion
2020-02-24
Completion
2020-02-24

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019120 on ClinicalTrials.gov